Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 2Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myeloid Malignancies 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Hematologic Diseases 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

fludarabine phosphate 23Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 18Mycophenolic Acid 16Cyclophosphamide 15Busulfan 15Tacrolimus 14Antilymphocyte Serum 14Cyclosporine 11Melphalan 10Rituximab 9Methotrexate 9Etoposide 8romidepsin 6Flow Cytometry 6Filgrastim 6Vorinostat 5Dexamethasone 5thymoglobulin 4fludarabine 4Sirolimus 4Granulocyte Colony-Stimulating Factor 4Carboplatin 4Calcium Dobesilate 4Bexarotene 4Alemtuzumab 4Thiotepa 3Therapeutics 3Radiotherapy 3Panobinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Cutaneous × cc-486 × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡